Akt1
Drug Details
- Description
- AKT1 inhibitors are drugs that target the AKT1 enzyme, which is involved in cell survival pathways, cancer cell proliferation, and resistance to apoptosis. These inhibitors aim to block the activity of AKT1 to suppress tumor growth and enhance the efficacy of other cancer treatments.
- Alternative Names
- AKT1 is also known as Protein Kinase B (PKB) or RAC-alpha serine/threonine-protein kinase.
- Key Genes
- The key genes involved with AKT1 include PIK3CA, PDK1, PTEN, and mTOR. These genes are part of the PI3K/AKT signaling pathway.
- Drug Use
- AKT1 inhibitors, such as ipatasertib and capivasertib, are used in cancer treatment to block the AKT1 pathway, which is involved in cell growth and survival.
- Genetic Factors Influencing Response
-
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Purchase Membership to Access Your Individual Drug Response Report